Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main coronary artery (LMCA) disease or three-vessel disease. This is why the current guidelines recommend CABG for LMCA or multivessel disease patients unless surgical risk is exceedingly high.

However, over the past decades, major advances in PCI have prompted studies evaluating whether PCI outcomes could surpass those of CABG. Although second-generation drug-eluting stents (DES) and fractional flow reserve (FFR)-guided PCI have led to significant improved clinical outcomes, the FAME 3 trial (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) failed to show non-inferiority for FFR-guided PCI vs. CABG in multivessel disease.

More recently, the introduction of intravascular imaging (IVI) has shown additional potential to improve clinical outcomes after PCI, particularly in complex coronary lesions. Considering these advances, reassessing the impact of IVI-guided PCI in LMCA or three-vessel disease patients, vs. CABG, is highly relevant to the current clinical practice.

Read also: Transradial Aortic Valvuloplasty: Is Minimalism Worth It?

The aim of this study — based on the RENOVATE-COMPLEX-PCI trial (Intravascular Imaging-Guided PCI versus Angiography-Guided PCI for Complex Coronary Artery Disease) and PCI and CABG institutional registries — was to compare clinical outcomes in LMCA or three-vessel disease patients undergoing IVI-guided PCI vs. CABG.

The primary endpoint was a composite of all-cause death, nonfatal myocardial infarction (MI), or stroke at 3 years. The secondary endpoint included all-cause death, nonfatal MI, stroke, cardiac death, and clinically driven repeat revascularization.

6,962 patients with left main or 3-vessel disease from the RENOVATE-COMPLEX-PCI trial (n = 1,639) and the institutional registry of Samsung Medical Center (2,972 patients underwent PCI and 6,600 patients underwent CABG) were analyzed. Overall, 848 patients received IVI-guided PCI, 987 angiography-guided PCI, and 5,127 CABG. Patients were mostly men, mean age 66.

Read also: Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring.

PCI patients showed a significantly higher risk vs CABG patients (13.3% vs. 10.8%; HR 1.23; 95% CI 1.05–1.44; P = 0.013). However, risk was comparable between IVI-guided PCI and CABG (8.7% vs. 10.8%; HR 0.77; 95% CI 0.59–1.01; P = 0.058). Propensity-score analysis showed similar results between IVI-guided PCI and CABG (9.5% vs. 9.4%; HR 0.98; 95% CI 0.69–1.40; P = 0.914).

Conclusion 

In this study, patients with LMCA or multivessel disease undergoing PCI had a significantly higher risk of all-cause death, nonfatal MI, or stroke vs patients undergoing CABG. However, IVI-guided PCI showed comparable clinical risk similar vs. CABG. Additional randomized clinical trials are required to confirm these findings.

Original Title: Intravascular Imaging-Guided PCI vs Coronary Artery Bypass Grafting for Left Main or 3-Vessel Disease

Reference: Sang Yoon Lee, MD et al JACC Cardiovasc Interv. 2025.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Andrés Rodríguez
Dr. Andrés Rodríguez
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...